Midatech and Monosol Rx file joint patent application
For nanoparticle film delivery systems
Midatech Group, a UK manufacturer of nanomedicines, and MonoSol Rx, a developer of pharmaceutical films based on its proprietary PharmFilm drug delivery technology, have filed a provisional US patent application for nanoparticle film delivery systems. The applications to the United States Patent and Trademark Office (USPTO) relate to therapeutic uses of nanoparticle-based proteins and peptides delivered in pharmaceutical films.
The nanoparticle film delivery system could be used to overcome the difficulties associated with the delivery of biologic therapies to the circulatory system, allowing for a more effective and convenient delivery system through buccal or sublingual administration.
The delivery system takes a therapy into the bloodstream without exposure to the gastrointestinal tract of the patient, avoiding the gastrointestinal destruction and/or side-effects associated with the oral drug delivery of certain molecules. The combination of these technologies also allows for the oral delivery of an entire class of therapies previously available primarily through injection.
The joint patent application relates to film delivery systems comprising nanoparticles, particularly for use in medicine, and includes methods and systems for the treatment of disorders of blood glucose in diabetic conditions.
Mark Schobel, ceo of MonoSol Rx, said: ‘Midatech’s ability to develop nanomedicines makes it an ideal partner to ensure we are able to fully exploit our PharmFilm technology.’
MonoSol Rx and Midatech have been collaborating on nanoparticle and PharmFilm drug delivery technologies since 2008.